Related Experiment Videos
[Thrombotic risk in myeloproliferative neoplasms: what the general practitioner needs to know]
A Casini1, F Boehlen, T Lecompte
1Service d'angiologie et d'hémostase HUG et Faculté de médecine de Geneve, 1211 Geneve 14. alessandro.casini@hcuge.ch
Abstract:
Polycythaemia vera, essential thrombocythemia and primary myelofibrosis are stem cell-derived clonal haemopathies classified in the group of myeloproliferative neoplasms. Their clinical course may be complicated by both arterial and venous (sometimes in unusual sites) thrombotic events. Although general risk factors contribute to the prevalence of thrombotic events in this population, some other risk factors are specifically associated with the myeloproliferative neoplasms. The treatment options are aspirin, anticoagulation, cytoreduction and phlebotomies.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis IV: Nursing Management
Venous Thrombosis I: Introduction
Pulmonary Embolism III: Nursing Management
Pulmonary Embolism I: Introduction
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...